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Background. HIV infected women have higher rates of infertility. Objective. The purpose of this literature review is to evaluate
the effectiveness of fresh IVF/ICSI cycles in HIV infected women. Materials and Methods. A search of the PubMed database was
performed to identify studies assessing fresh nondonor oocyte IVF/ICSI cycle outcomes of serodiscordant couples with an HIV
infected female partner.Results and Discussion. Ten studies met the inclusion criteria.Whenever a comparison with a control group
was available, with the exception of one case, ovarian stimulation cancelation rate was higher and pregnancy rate (PR) was lower in
HIV infected women. However, statistically significant differences in both rates were only seen in one and two studies, respectively.
A number of noncontrolled sources of bias for IVF outcome were identified. This fact, added to the small size of samples studied
and heterogeneity in study design and methodology, still hampers the performance of a meta-analysis on the issue. Conclusion.
Prospective matched case-control studies are necessary for the understanding of the specific effects of HIV infection on ovarian
response and ART outcome.
1. Introduction
The human immunodeficiency virus (HIV) epidemic arose
from zoonotic infections with simian immunodeficiency
viruses from African primates. Since then, the global epi-
demiology of HIV infection has changed markedly: the
prevalence of HIV has increased from 31 million in 2002 to
36.9 million in 2014, essentially due to prolonged survival
caused by antiretroviral therapy, whereas the global incidence
has decreased from 3.3million in 2002 to 2million in 2014 [1].
Since the introduction of antiretroviral therapies, two
major medical achievements have beenmade, allowingmany
couples with an HIV positive partner to consider pregnancy
planning:
(1) Life expectancy of infected patients as well as their life
quality has dramatically improved during the last 10
years [2].
(2) A significant reduction inmother-to-childHIV trans-
mission (MTCT) has been observed, especially in
developed countries, with transmission rates lower
than 1% to 2%, compared to 14% to 42% without any
intervention. This has been achieved with the use of
antiretroviral drug combinations during pregnancy
and labor/delivery, neonatal prophylaxis, elective cae-
sarean delivery, and avoidance of breast feeding [3].
Over 80%of people infectedwithHIV are of reproductive
age (15 to 44 years old). Reports suggest that there are
currently more than 140,000 HIV serodiscordant heterosex-
ual couples in the United States (US), approximately 50%
of whom having reproductive plans [4]. According to the
National Perinatal HIVHotline andCliniciansNetwork, calls
pertaining to HIV serodiscordant couples and their options
for safer conception have increased significantly between
2006 and 2011 [5].
Managing HIV infected patients with a childbearing
wish involves a multidisciplinary approach, ideally including
maternal-fetal medicine specialists, HIV/AIDS specialists,
neonatologists, pediatricians, psychiatrists, social workers,
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and reproductive endocrinologists [6]. Preconception coun-
seling is highly recommended among HIV serodiscordant
and seroconcordant couples, allowing them to make more
informed choices in order to reduce sexual transmission and
improving pregnancy outcome [7]. However, a recent survey
of HIV infected women who had been or were pregnant at
the time of the questionnaire showed that more than half of
them did not have preconception counseling [8]. Evaluating
the need for antiretroviral therapy should be part of the initial
assessment of preconception counseling. Any concurrent
sexually transmitted infection should be treated and safe
sexual practices should be encouraged [9].
Infertility affects approximately 15% of the general pop-
ulation and HIV infected patients, both men and women,
have higher rates of infertility than their HIV negative
counterparts [10, 11].
In serodiscordant couples in which the male partner
is infected, assisted reproductive technology (ART) is the
safest way to prevent sexual transmission. After the sperm-
washing (SW) procedure, there are two main options to
achieve a pregnancy: intrauterine insemination (IUI) and
in vitro fertilization (IVF)/intracytoplasmic sperm injection
(ICSI). In couples with a normal fertility evaluation, IUI is
an effective approach. If semen analysis is abnormal, then
IVF/ICSI is undoubtedly the treatment to be offered [6]. SW
eliminates round cells, seminal plasma, and the majority of
immotile sperm. Spermatozoa are isolated by sequential den-
sity gradient and swim-up techniques and are subsequently
tested by PCR assays for the presence ofHIVRNA [12]. A sys-
tematic review andmeta-analysis summarized the experience
with serodiscordant couples with an infected male partner
until 2013, with 2,393 SW-IUI and 780 SW-IVF treatment
cycles documented [13]. The authors concluded that HIV
infected men with noninfected partners have pregnancy and
live birth rates with ART comparable to seronegative couples.
In serodiscordant couples in which the female partner
is infected, pregnancy can be achieved without the risk of
sexual transmission by self-insemination around the time of
ovulation [6]. If conception does not occur after more than
six cycles of self-insemination, or if a preexisting fertility
problem was diagnosed, the use of ART should be envisaged
[7].
Most of the reports so far published on IUI or IVF treat-
ments performed in serodiscordant couples refer to infected
male partners. Very few studies have addressed IVF outcome
in serodiscordant couples with an HIV infected female part-
ner.The purpose of this review is to evaluate the effectiveness
of fresh nondonor oocyte IVF/ICSI treatments performed in
this population. Control over variables that are traditionally
known to influence IVF/ICSI outcome, such as female age,
ovarian reserve, race/ethnicity, Body Mass Index (BMI),
tobacco consumption, the presence of tubal disease, and the
number of embryos replaced in the uterus, was ascertained in
the studies found.
2. Materials and Methods
A search of the PubMed database was performed in order to
identify all studies involving ART including the HIV infected
population published until July 2014. The search terms used
were “HIV” AND “assisted reproduction,” “HIV” AND
“assisted reproductive technology,” “HIV” AND “in vitro
fertilization,” and “HIV” AND “infertility”. Abbreviations
such as “IVF” and “ICSI” were also used. An initial list of
626 studies was obtained. Inclusion criterion was studies
assessing fresh nondonor oocyte IVF/ICSI cycle outcomes of
serodiscordant couples with an HIV infected female partner.
References with abstracts that demonstrated them to be
unrelated to the IVF/ICSI cycle outcomes of serodiscordant
couples with an HIV infected female partner were excluded
without full text assessment, as were reviews and case reports.
All original articles with abstracts that indicated them to
be within the scope of this study were fully assessed; when
this assessment was confirmed, they were included in the
review. Articles in languages other than English, Portuguese,
Spanish, or French were excluded. Ten studies were finally
included. Figure 1 summarizes the steps involved in literature
selection based on Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [24].
3. Results
Studies analyzed reported on ART treatments performed in a
total of 342 HIV infected women, with a mean age of 35.4
years, who underwent 516 IVF/ICSI cycles (Table 1). The
average CD4 count ranged from “>200” to 712 cells/mm3,
48% to 100% of patients in each study had undetectable viral
loads, and 44% to 95% of them were being treated with
combined antiretroviral therapy.
Table 1 shows baseline characteristics of study and control
groups and Table 2 shows the outcomes of ovarian stimula-
tion and IVF.
Among the studies included in this review, data concern-
ing ovarian response to stimulation in HIV infected patients
can be summarized as follows: some of the initial studies
report the need of higher doses of gonadotropin to achieve
satisfactory ovarian response (Terriou et al. 2005 [16]; Coll
et al. 2006 [17]), while a normal response to stimulation is
described in infected women who are in good general health
conditions and reach egg pick-up (Martinet et al. 2006 [18]).
Data from most recent studies suggest that a normal ovarian
response is seen in these patients (Manigart et al. 2006 [19],
Douglas et al. 2009 [20], Prisant et al. 2010 [21], Santulli
et al. 2011 [22], and Nurudeen et al. 2013 [23]) (Table 2).
However, in the nine studies that assessed the cancellation
rate of ovarian stimulation inHIV infected patients, although
significance was observed in only one of them (15.2% versus
4.9% in the control group), in all the instances in which a
comparison could bemade cancellation rate was higher in the
study group than in controls (Table 2).
In study groups, the clinical PR per stimulation cycle
initiated varied from 6.7% to 24.1% and the clinical PR
per embryo transfer varied from 9.1% to 63% (Table 2).
Unfortunately, not all studies mentioned the rate per cycle
initiated. A summary of the conclusions of the six studies that
compared the PRs in HIV infected women with those from
noninfected controls is (Table 2) as follows:
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Figure 1: Flow chart for the search methodology.
(i) In two studies, HIV infectedwomen had a statistically
significantly lower PR (Ohl et al. 2003 [14], Coll et al.
2006 [17]).
(ii) In three studies, the PR of HIV infected women
was not statistically significantly different from that
of control subjects, but lower values were observed
(Martinet et al. 2006 [18], Santulli 2011 et al. [22], and
Nurudeen et al. 2013 [23]).
(iii) In one study, the PR of HIV infected women was not
statistically significantly different from that of control
subjects, but a higher value was observed (Prisant et
al. 2010 [21]).
In all studies, PR was reported per embryo transfer, with
the exception of two cases of PR per cycle initiated [16, 19]
and one of PRs per oocyte retrieval [22]. Noteworthy, vertical
transmission of HIV infection was zero.
Concerning variables that are traditionally known to
influence IVF/ICSI outcome, data from studies can be sum-
marized as follows.
3.1. Female Age. Seven studies included in this review were
age-matched. In only one study, ART results were stratified
by age: in both age groups (<35 and ≥35 years), infected and
control patients had similar IVF/ICSI clinical outcomes with
similar clinical PRs per embryo transfer [23].
3.2. Ovarian Reserve. Six studies included in this review
evaluated the ovarian reserve, but only five of them had a
control group (Table 1):
(i) In one of them, the comparison between early follic-
ular phase serum FSH of HIV infected women and
controls showed a statistically significant difference
(9.0 ± 2.4 versus 7.0 ± 2.9 IU/L, resp., 𝑝 < 0.001) (Ohl
et al. 2003 [14]).
(ii) In the other four studies, HIV infected women and
controls had similar values for markers of ovarian
reserve. FSH and HAM levels and antral follicle
count (AFC) were evaluated (Terriou et al. 2005 [16];
Douglas et al. 2005 [20]; Santulli et al. 2011 [22];
Nurudeen et al. 2013 [23]).
3.3. Race/Ethnicity. In our review, only two studies docu-
mented patients’ race/ethnicity [18, 23]. In both of them, the
proportion of black women was significantly higher in the
study group and this was mentioned as a possible source of
bias.
3.4. BodyMass Index (BMI). Only two of the studies analyzed
evaluated BMI (Table 1):
(i) In one of them, HIV infected women had higher BMI
than control subjects (24.2 versus 22.9, 𝑝 = 0.032)
(Santulli et al. 2011 [22]).
(ii) In the other one, HIV infected women and controls
had similar BMI (Nurudeen et al. 2013 [23]).
3.5. Tobacco. Of the studies analyzed in this review, only two
controlled for tobacco consumption:
(i) In the first of them, no differences were found
between HIV infected women and controls (Santulli
et al. 2011 [22]).
(ii) In the other one, in the group of women ≥35 years of
age, infected patients smoked significantlymore often
than controls (16% versus 0%; 𝑝 < 0.05). Although
parameters of ovarian reserve, the number of mature
oocytes retrieved, and fertilization and clinical PRs
per embryo transfer were similar in HIV infected
women and controls, live birth rates per embryo
6 Infectious Diseases in Obstetrics and Gynecology
transfer were significantly lower for HIV infected
women (6% versus 24%, 𝑝 = 0.04) (Nurudeen et al.
2013 [23]). Unfortunately, cancelation rates were not
compared between groups.
3.6. Tubal Disease. In four of the studies reviewed, the inci-
dence of tubal disease could be compared between the study
and control groups and in all of them a higher proportion
of tubal disease in HIV infected women was documented,
confirming previous reports on the literature [25] (Table 1). In
two of them, a statistically significant difference was observed
(Santulli et al. 2011 [22] and Nurudeen et al. 2013 [23]).
3.7. Number of Embryos Replaced per Transfer. In the studies
analyzed, different criteria were adopted regarding embryo
transfer (Table 2). In three of them, the authors reported
they were more likely to replace a lower number of embryos
in infected women (Terriou et al. 2005 [16]; Martinet et al.
2006 [18]; Santulli et al. 2011 [22]). However, documentation
of a significant reduction in the mean number of embryos
transferred was seen in only two of these (Martinet et al. 2006
[18]; Santulli et al. 2011 [22]).
4. Discussion
The variability of results observed in the studies analyzed
can be mostly related to the small size of the samples
studied, heterogeneity in study design, andmethodology and
incomplete control over potential confounding data. These
limitations do not allow for the implementation of a statistical
approach thatmight lead to solid conclusions, such as ameta-
analysis.
Variables that are traditionally known to influence





(4) Body Mass Index (BMI).
(5) Tobacco consumption.
(6) Tubal disease.
(7) Number of embryos replaced.
A summary of the variables controlled per study is
available in Table 3 and aspects to be considered regarding
each of them are as follows.
4.1. Female Age. Population studies from areas where no
consistent methods of birth control are applied show that
natural fertility starts to decline after the age of 30, has its
decline accelerated in the mid-30s, and ends at a mean age
of 41 years [26]. The age-related effect on female fertility has
also been shown in numerous reports on the results of IVF
treatments due to a progressive decline on oocyte quality and
quantity. The implantation rate per embryo clearly decreases
after the age of 35 and the same has been shown for the
probability of a live birth in IVF [27].
Due to this knowledge, control over female age is of
paramount importance in any study on IVF treatment out-
come. Such was not seen in three of the ten studies included
in this review.
4.2. Ovarian Reserve. ART requires controlled ovarian stim-
ulation for the achievement of improved efficacy. Currently, it
is not consensual that HIV infection affects ovarian reserve.
Seifer et al. evaluated the markers of ovarian follicular
reserve and reproductive ageing in 187 HIV infected women
not diagnosed as infertile [28]. Early follicular phase FSH,
estradiol, inhibin B, and anti-Mullerian hormone (AMH)
levels were measured. No evidence was found that HIV
infection affects ovarian ageing. On the other hand, Ohl et al.
measured serum FSH, inhibin B, AMH, and the antral follicle
count (AFC) in 78 HIV infected women [29]. Mean FSH was
36%higher than that seen in the control group, whereasmean
inhibin B and AMH were 57% and 23% lower, respectively.
AFC was also significantly lower in the study group.
The possible influence of combined antiretroviral therapy
on ovarian reserve and ovarian response to stimulation is not
clear either. Side effects of the use of antiretroviral drugs such
as mitochondrial dysfunction or modification in the lipid
metabolism and insulin resistance could have consequences
on folliculogenesis and ovulation regulatory processes [2, 30].
Oocytes from infertile HIV infected women on combined
antiretroviral therapy were reported to have 32% depletion in
mtDNA in comparison to infertile uninfected controls (𝑝 <
0.05) and depletion was even stronger in patients who failed
to become pregnant in IVF treatments [31].
4.3. Race/Ethnicity. A growing number of studies have
investigated the association between race/ethnicity and ART
outcomes. Most of the studies have focused on comparisons
between white Caucasian and black women and some have
identified that the last group is more likely to have a
diagnosis of tubal factor infertility, leiomyoma/uterine factor
infertility, a longer duration of infertility before ART, and
higher miscarriage/stillbirth rates [32–36]. Race/ethnicity as
a risk factor for poor ART outcomes has been consistently
acknowledged in recent large studies, even after adjusting
for many confounding factors [37]. This may certainly be a
source of bias for data collected in this review.
4.4. Body Mass Index (BMI). Overweight and obesity are
well-described risk factors for infertility, particularly as they
relate to ovulation disorders. In spite of conflicting results of
studies regarding the effect of high BMI on ART outcome,
a systematic review and meta-analysis published in 2011
showed that overweight or obese women (BMI ≥ 25) had
significantly lower clinical pregnancy (RR = 0.90, 95% CI
0.85–0.94) and live birth rates (RR = 0.84, 95% CI 0.77–0.92)
and a significantly higher miscarriage rate (RR = 1.31, 95%
CI 1.18–1.45) [38]. The analysis of overweight women alone
(BMI ≥ 25–29.9) also showed lower clinical pregnancy (RR =
0.91, 95% CI 0.86–0.96) and live birth rates (RR = 0.91, 95%
CI 0.85–0.98) and higher miscarriage rate (RR = 1.24, 95% CI
1.13–1.35), compared to womenwith BMI < 25. In conclusion,
increased BMI is associated with adverse outcomes in women






























































































































































































































































































































8 Infectious Diseases in Obstetrics and Gynecology
undergoing IVF/ICSI treatment, including lower live birth
rates.
Increasing overweight and obesity in the HIV infected
population were not seen until two decades ago. This rel-
atively new reality has been attributed to several factors,
such as better health due to combined antiretroviral therapy
and improved life expectancy, which leads to obesity trends
similar to those seen in the general population [39]. This
parameter was not properly controlled for in the majority of
studies analyzed here.
4.5. Tobacco. Over the last few decades, the prevalence
of cigarette smoking among women of reproductive age
has increased, reaching, in 2006, 33% in Europe and 28%
in the USA [40], and is highly prevalent among persons
infected with HIV [41]. Studies on IVF showed that cigarette
smoking has deleterious effects onmany aspects of treatment:
ovarian responsiveness to gonadotropins, number of oocytes
retrieved, fertilization, implantation, and early placentation
[42].
4.6. Tubal Disease. In the studies reviewed, a higher pro-
portion of tubal disease in HIV infected women was docu-
mented, confirming previous reports on the literature [25].
It is important to notice that many studies collected data at
times during which it was still not a standard procedure to
remove hydrosalpinx before IVF, which may have reduced
live birth rates and constituted a source of bias [43].
Another factor associated with tubal disease that should
be considered is the personal history of pelvic inflammatory
disease. This condition has been shown to reduce ovarian
response to stimulation due to direct damage to the ovaries
and follicle loss or due to mechanical alterations of follicular
development [18].
4.7. Number of Embryos Replaced per Transfer. The rate of
preterm delivery and multiple gestations after ART is of
particular concern for HIV infected women. Preterm labor
or premature rupture of membranes may increase the risk
of HIV vertical transmission [44]. Elective single embryo
transfer for HIV infected women shall be considered in order
to reduce the risk of multiple gestations [15]. A lower number
of embryos replaced in HIV positive women may obviously
contribute to lower pregnancy and live birth rates per transfer.
5. Conclusions
Data on PR in IVF/ICSI treatments performed in couples
with HIV infected women are conflicting and it is still not
clear if these patients display worse clinical outcomes per
cycle initiated when compared to the general population.
The same can be said specifically about ovarian response to
stimulation, though a tendency for higher cancellation rates
seems to be observed.
The small size of the samples studied and heterogeneity in
study design and methodology make it difficult to draw clear
conclusions about the impact of HIV infection in women on
IVF outcome. Incomplete control over confounding variables
(such as age, race/ethnicity, BMI, tobacco consumption, tubal
disease, history of pelvic inflammatory disease, duration
of infertility, and the number of embryos replaced) is of
special concern. Altogether, such limitations hamper the
performance of a proper meta-analysis.
In the future, prospective matched case-control studies
are needed to understand the specific effects of HIV infection
on ovarian response and ART outcome. Available data sug-
gest some impact of HIV infection on ovarian function and
IVF outcome, but noncontrolled sources of bias in published
studies do not allow for definitive conclusions.
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